Contineum Therapeutics Past Earnings Performance
Past criteria checks 0/6
Contineum Therapeutics has been growing earnings at an average annual rate of 30.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 31.8% per year.
Key information
30.2%
Earnings growth rate
111.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 31.8% |
| Return on equity | -16.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Contineum Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -29 | 11 | 32 |
| 30 Jun 24 | 0 | -20 | 9 | 29 |
| 31 Mar 24 | 50 | 0 | 8 | 31 |
| 31 Dec 23 | 50 | 3 | 7 | 27 |
| 30 Sep 23 | 50 | -3 | 7 | 23 |
| 31 Dec 22 | 0 | -24 | 7 | 16 |
Quality Earnings: CTNM is currently unprofitable.
Growing Profit Margin: CTNM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CTNM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CTNM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTNM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: CTNM has a negative Return on Equity (-16.87%), as it is currently unprofitable.